Ratio Therapeutics, a clinical-stage company specializing in radiopharmaceuticals for cancer, has successfully closed a $70 million Series C financing round. This new capital injection, which brings the company's total funding to over $240 million, saw participation from both existing and new high-profile investors. The proceeds are earmarked to accelerate the development of its advanced therapeutic pipeline and expand its manufacturing capabilities.
Strategic Allocation of New Capital
A significant portion of the new funding will be dedicated to advancing the company's ongoing ATLAS clinical study. This trial evaluates Ratio's lead asset, [Ac-225]RTX-2358, for the treatment of advanced sarcomas. The company also plans to use the capital to propel its next-generation radioligand therapy (RLT) candidate into clinical trials.
Beyond its current clinical programs, Ratio intends to expand its discovery pipeline into new, high-value oncology targets. This strategic expansion aims to extend the company's proprietary radiopharmaceutical platform to address additional tumor types. Such efforts are focused on areas with significant unmet medical needs and substantial market potential for innovative treatments.
The financing will also support the enhancement of Ratio's proprietary technology and the scaling of its manufacturing infrastructure. This includes strengthening its Trillium and Macropa platforms, which are central to its drug development process. These investments are crucial for supporting the growing pipeline and meeting anticipated future commercial demand for its therapies.
Investor Confidence and Market Position
The financing round featured strong participation from existing investors Duquesne Family Office and Bristol Myers Squibb. They were joined by a notable group of new investors, including Catalio Capital Management, Eli Lilly and Company, and the Wasatch Group. This blend of continued and new support underscores the growing confidence in Ratio's platform and its potential impact.
Sue Meng, Managing Director of Duquesne Family Office, highlighted the firm's conviction in Ratio's potential to change patient outcomes. She praised the company as a leader in radiopharmaceutical innovation that has consistently demonstrated strong execution. Meng noted Ratio's success in achieving clinical milestones, forging strategic partnerships, and building essential manufacturing infrastructure.
Dr. Jack Hoppin, Ratio's Chief Executive Officer, stated that the financing reflects the confidence investors have in the company's progress. He emphasized that the proceeds are instrumental for advancing the ATLAS trial and preparing for a fifth Investigational New Drug (IND) filing. The funding will support the entire lifecycle of its targeted radiopharmaceuticals, from development to supply.
Advancing Radiopharmaceutical Innovation
Ratio Therapeutics is focused on systematically engineering radiopharmaceuticals to create best-in-class cancer treatments with an optimized therapeutic index. Its lead program, [Ac-225]RTX-2358, is a fibroblast activation protein (FAP) targeted therapeutic currently in a Phase 1/2 trial. This approach exemplifies the company's commitment to precision oncology and targeted drug delivery for improved patient results.
The company's pipeline is supported by its proprietary Trillium pharmacokinetic tuning technology and its Macropa chelator platform. These technologies enable the development of a broad range of therapies, including a next-generation GRPR program and other mono- and bispecific radioligand treatments. This technological foundation is a key differentiator for Ratio in the competitive radiopharmaceutical landscape.
This $70 million Series C financing marks a pivotal moment for Ratio Therapeutics, providing substantial resources to advance its clinical and preclinical programs. The investment will enable the company to accelerate its lead asset, expand its pipeline, and scale its manufacturing operations. With strong backing from prominent investors, Ratio is well-positioned to continue its mission of developing innovative radiopharmaceutical treatments for cancer patients.